
Menveo is a vaccine that contains Meningococcal Groups A, C, Y, and W-135 oligosaccharides, each conjugated to a CRM protein, and is intended for intramuscular injection. It is prepared as a sterile liquid and each dose contains specific amounts of these oligosaccharides along with CRM protein. The vaccine formulation includes residual formaldehyde but does not contain any preservatives or adjuvants. Menveo is typically used to immunize against meningococcal diseases caused by the specified strains in an effort to reduce incidence and severity.